A new “vaccine-like” HIV drug that currently costs over US$40,000 (S$54,000) per person a year could be made for as little as US$40, researchers estimated on July 23. The antiretroviral drug Lenacapavir, developed by US pharmaceutical giant Gilead, has been hailed as a potential game changer in the fight against HIV. Early trials have found […]
The post New ‘vaccine-like’ HIV drug could cost just $40: researchers appeared first on Insider Paper.